Epilepsia Publishes Results From Two Studies Of Eisai's Perampanel

Update: Fycompa (perampanel) Now FDA Approved - October 22, 2012

WOODCLIFF LAKE, N.J., Aug. 20, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset Seizures: Results of Randomized Global Phase III Study 305," and "Perampanel, A Selective, Non-Competitive AMPA Receptor Antagonist, as Adjunctive Therapy for Refractory Partial-Onset Seizures: Interim Results from Phase III, Open-Label Extension Study 307," were published today in the online publication of  Epilepsia.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

The marketing authorization application for perampanel is currently under review with the U.S. Food and Drug Administration.

About Perampanel
Perampanel is an orally administered, selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist, discovered and being developed by Eisai. 

About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business.  Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. 

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com/US

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.  Eisai employs approximately 11,000 employees worldwide. 

 

 

 


SOURCE Eisai Inc.

 


PR Newswire (http://s.tt/1lgUq)

 

Posted: August 2012

View comments

Hide
(web5)